As a part of the agreement, the physiological characteristics of the adult autologous vascular cells which form the basis of the IntelliCell product will be discovered.
IntelliCell CEO Steven Victor said, "IntelliCell believes that important contributions for better medicine will result from research collaborations with our university research colleagues."
The IntelliCell also plans to explore combination therapies with patent pending bio-engineered products under development.
The University of Florida biomedical engineering and biomaterials professor Jon Dobson said the use of adult autologous stem cells to repair and regenerate tissues are of great interest to personalized medicine researchers.